Lifecore Biomedical, Inc. (NASDAQ:LFCR) Holdings Cut by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 72.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,966 shares of the company's stock after selling 39,433 shares during the period. BNP Paribas Financial Markets' holdings in Lifecore Biomedical were worth $111,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LFCR. Greenhaven Road Investment Management L.P. grew its stake in shares of Lifecore Biomedical by 62.2% during the fourth quarter. Greenhaven Road Investment Management L.P. now owns 3,616,146 shares of the company's stock valued at $26,868,000 after acquiring an additional 1,387,362 shares in the last quarter. 325 Capital LLC lifted its position in shares of Lifecore Biomedical by 57.9% during the fourth quarter. 325 Capital LLC now owns 2,162,466 shares of the company's stock worth $16,067,000 after purchasing an additional 792,681 shares during the last quarter. Invesco Ltd. bought a new position in shares of Lifecore Biomedical during the fourth quarter worth about $4,128,000. DCF Advisers LLC lifted its position in shares of Lifecore Biomedical by 87.2% during the fourth quarter. DCF Advisers LLC now owns 539,989 shares of the company's stock worth $4,012,000 after purchasing an additional 251,511 shares during the last quarter. Finally, Alpha Wave Global LP bought a new position in shares of Lifecore Biomedical during the fourth quarter worth about $866,000. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Lifecore Biomedical Stock Up 1.5%

Shares of LFCR stock traded up $0.10 during trading hours on Monday, hitting $6.87. 177,751 shares of the company were exchanged, compared to its average volume of 241,249. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. Lifecore Biomedical, Inc. has a one year low of $3.68 and a one year high of $7.99. The business's 50-day simple moving average is $6.52 and its two-hundred day simple moving average is $6.57. The stock has a market capitalization of $254.36 million, a price-to-earnings ratio of -12.27 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last issued its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. The company had revenue of $35.15 million for the quarter, compared to the consensus estimate of $33.23 million. Sell-side analysts predict that Lifecore Biomedical, Inc. will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lifecore Biomedical news, major shareholder Aron R. English sold 1,139,504 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $6.50, for a total value of $7,406,776.00. Following the transaction, the insider now owns 414,599 shares of the company's stock, valued at $2,694,893.50. This trade represents a 73.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 1,485,182 shares of company stock valued at $9,824,031 over the last quarter. Insiders own 32.20% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, William Blair initiated coverage on shares of Lifecore Biomedical in a research report on Wednesday, May 21st. They set an "outperform" rating on the stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.